Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 698-707

  Eroles, Pilar ^a   Bosch, Ana ^a   Alejandro Perez Fidalgo J ^a   Lluch, Ana ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

AMPK; Angiogenesis; Breast cancer; ER; HER2; Intrinsic subtypes; PARP inhibitors; PI3K AKT mTOR pathway; Platinum compounds; Signaling pathways

Indexed keywords

ADENYLATE KINASE; ANASTROZOLE; AROMATASE INHIBITOR; BRCA1 PROTEIN; CAVEOLIN 1; CAVEOLIN 2; CLAUDIN; CLAUDIN 3; CLAUDIN 4; CYTOKERATIN 17; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; HERMES ANTIGEN; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; NESTIN; OLAPARIB; P CADHERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR GATA 3; UNINDEXED DRUG;

ANGIOGENESIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); GENE EXPRESSION PROFILING; GENETIC MODEL; GENOMIC INSTABILITY; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL DEVICE; MOLECULAR BIOLOGY; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TECHNOLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 84861708138     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.11.005     Document Type: Review

References (97)

1. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23(19):4265-4274.
2. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353(16):1659-1672.
3. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697.
4. Van Cutsem E., Kohne C.H., Lang I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29(15):2011-2019.
5. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
6. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101(36):13306-13311.
7. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
8. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100(18):10393-10398.
9. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826.
10. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 25:1999-2009.
11. Chang H.Y., Nuyten D.S., Sneddon J.B., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005, 102(10):3738-3743.
12. Ma X.J., Wang Z., Ryan P.D., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5(6):607-616.
13. Foekens J.A., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006, 24(11):1665-1671.
14. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-679.
15. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98(4):262-272.
16. Loi S., Haibe-Kains B., Desmedt C., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25(10):1239-1246.
17. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355(6):560-569.
18. Weigelt B., Hu Z., He X., et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005, 65(20):9155-9158.
19. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874.
20. Kennecke H., Yerushalmi R., Woods R., et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28(20):3271-3277.
21. Guarneri V., Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 2009, 14(7):645-656.
22. Cheang M.C., Chia S.K., Voduc D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101(10):736-750.
23. Dowsett M., Nielsen T.O., A'Hern R., et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011, [Epub ahead of print].
24. Parker J.S., Prat A., Cheang M.C.U., et al. Breast cancer molecular subtypes predict response to anthracycline/taxane-based chemotherapy. Cancer Res 2009, 69(24 Suppl. 3). 10.1158/0008-5472.SABCS-1109-2019.
25. http://www.clinicaltrial.gov/.
26. Parker J.S., Prat A., Mullins M., et al. Supervised risk predictor of breast cancer based on intrisic subtypes. J Clin Oncol 2009, 27(8):1160-1167.
27. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5(1):5-23.
28. Staaf J., Ringner M., Vallon-Christersson J., et al. Identification of subtypes in human epidermal growth factor receptor 2 - positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 2010, 28(11):1813-1820.
29. Gianni L., Dafni U., Gelber R.D., et al. Treatment with trastuzumab for 1year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011, 12(3):236-244.
30. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
31. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
32. Baselga J., Bradbury Ian, Eidtmann H., et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Cancer Res 2011, 70(S3-3). 10.1158/0008/5472.SABCS1110-S1153-1153.
33. Gianni L, Pienkowski T, Im, Y-H, et al. Neoadjuvant pertuzumab(P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (NeoSphere). San Antonio Breast Cancer Symposium 2010;(abstract S3-2).
34. Bosch A., Eroles P., Zaragoza R., Vina J.R., Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010, 36(3):206-215.
35. Livasy C.A., Karaca G., Nanda R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19(2):264-271.
36. Smid M., Wang Y., Zhang Y., et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008, 68(9):3108-3114.
37. Kreike B., van Kouwenhove M., Horlings H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9(5):R65.
38. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10(16):5367-5374.
39. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100(14):8418-8423.
40. Dent R., Trudeau M., Pritchard K.I., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13(15):4429-4434.
41. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11(16):5678-5685.
42. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):123-134.
43. Weigelt B., Mackay A., A'Hern R., et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010, 11(4):339-349.
44. Herschkowitz J.I., Simin K., Weigman V.J., et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8(5):R76.
45. Prat A., Parker J.S., Karginova O., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12(5):R68.
46. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69(10):4116-4124.
47. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thurlimann B., Senn H.J. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 2011, 22(8):1736-1747.
48. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24(23):3726-3734.
49. Albain K.S., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11(1):55-65.
50. Wirapati P., Sotiriou C., Kunkel S., et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10(4):R65.
51. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26):2666-2676.
52. Desmedt C., Di Leo A., de Azambuja E., et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011, 29(12):1578-1586.
53. Mello-Grand M., Singh V., Ghimenti C., et al. Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. Breast Cancer Res Treat 2010, 121(2):399-411.
54. Sabine V.S., Sims A.H., Macaskill E.J., et al. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. Breast Cancer Res Treat 2010, 122(2):419-428.
55. Fumagalli D., Desmedt C., Ignatiadis M., Loi S., Piccart M., Sotiriou C. Gene profiling assay and application: the predictive role in primary therapy. J Natl Cancer Inst Monogr 2011, 2011(43):124-127.
56. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
57. O'Shaughnessy J., Osborne C., Pippen J.E., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011, 364(3):205-214.
58. O'Shaughnessy L.S., Schwartzberg M.A., Danso A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastasic triple-negative breast cancer (TNBC). J Clin Oncol 2011, 29. [abstr 1007].
59. Cheng N., Chytil A., Shyr Y., Joly A., Moses H.L. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res 2008, 6(10):1521-1533.
60. Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28(7):1124-1130.
61. http://www.clinicaltrials.gov/ct2/results?term=TDM1&recr=Open&rslt=&type=Intr&cond=&int&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e.
62. Krop IE, Modi S, Elias A, et al. A phase Ib study evaluating safety, tolerability, pharmacokinetics (PK), and activity of the phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941 in combination with trastuzumab-MCC-DM1 (T-DM1) in patients with advanced HER2-positive breast cancer. Cancer Research 2010; 70 [Abstract P6-15-02].
63. Warburg O. The metabolsim of tumours: investigations from the Kaiser Wilhem Institute for Biology, Berin-Dahlem. London, UK: Arnold Constable 1930.
64. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100(3):328-341.
65. Baserga R., Peruzzi F., Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003, 107(6):873-877.
66. Gonzalez-Angulo A.M., Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010, 16(6):1695-1700.
67. Wan X., Harkavy B., Shen N., Grohar P., Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26(13):1932-1940.
68. Jones R.A., Campbell C.I., Gunther E.J., et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007, 26(11):1636-1644.
69. Eroles P., Bosch A., Bermejo B., Lluch A. Mechanisms of resistance to hormonal treatment in breast cancer. Clin Transl Oncol 2010, 12(4):246-252.
70. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 2011, 16(1):12-19.
71. Berns K., Horlings H.M., Hennessy B.T., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12(4):395-402.
72. Tabernero J., Rojo F., Calvo E., et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26(10):1603-1610.
73. Di Cosimo S., Bendell J.C., Cervantes-Ruiperez A. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol 2010, 28(15):3008.
74. Gwinn D.M., Shackelford D.B., Egan D.F., et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008, 30(2):214-226.
75. Hardie D.G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007, 8(10):774-785.
76. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009, 69(19):7507-7511.
77. Jiralerspong S., Palla S.L., Giordano S.H., et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009, 27(20):3297-3302.
78. Dignam J.J., Wieand K., Johnson K.A., Fisher B., Xu L., Mamounas E.P. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 2003, 95(19):1467-1476.
79. Loi S., Milne R.L., Friedlander M.L., et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(7):1686-1691.
80. Reeves G.K., Pirie K., Beral V., Green J., Spencer E., Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007, 335(7630):1134.
81. Judd H.L., Shamonki I.M., Frumar A.M., Lagasse L.D. Origin of serum estradiol in postmenopausal women. Obstet Gynecol 1982, 59(6):680-686.
82. Siiteri P.K. Adipose tissue as a source of hormones. Am J Clin Nutr 1987, 45(1):277-282.
83. Sestak I., Distler W., Forbes JF., et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010, 28(21):3411-3415.
84. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257.
85. Baluk P., Hashizume H., McDonald D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005, 15(1):102-111.
86. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28(20):3239-3247.
87. Robert N.J., Dieras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29(10):1252-1260.
88. O'Shaughnessy J., Miles D., Gray R.J., et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010, 28(15):12-14.
89. O'Shaughnessy J., Romieu G., Diéras V., et al. Meta-analysis of patients with triple-negative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). Cancer Res 2011, 70. [abstract P6-12-03].
90. Miles D.W., Romieu G., Dieras V., et al. Meta-analysis of patients (pts) previously treated with taxanes from three randomized trials of bevacizumab (bv) and first-line chemotherapy as treatment for metastatic breast cancer (MBC). Ann Oncol 2010, 21(8). [abstract 279PD].
91. Lluch A, Martínez de Dueñas E, Eroles P. Clasificación molecular del cáncer de mama. Cáncer de mama en el 2010. Estado actual del diagnóstico y tratamiento. La Fundación de Estudios Mastológicos (FEMA), editors. Madrid 2010.
92. Garber J.E., Richardson A., Harris L.N., et al. Neo-adjuvant cisplatin (CDDP) in "triple-negative" breast cancer. Breast Cancer Res Treat 2006, 105(1). [abstract S149].
93. O'Shaughnessy J., Weckstein D.J., Vukelja S.J., et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007, 106(1):12-14. [abstract S32].
94. Carey L.A., Rugo H.S., Marcom P.K., et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008, 26:1009.
95. Gronwald J., Byrski T., Huzarski T., et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol 2009, 27(15):12-15. [abstr 502].
96. Ryan T.N., Isakoff S.J. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol 2009, 27(15). [abstr 551].
97. Baselga J., Stemmer S., Pego A., et al. Cetuximab+cisplatin in estrogen receptor-negative, progesterone receptor negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Res 2010, 70(24).